Genmab

	23/3 17:36 af E L	the question on Tisotumab Vedotin was not very precise, but i think Jan is referring to peak sales for cervical cancer there; that amount could get much higher if it works in other indications
	23/3 17:35 af Solsen	Mærkeligt at jeg ikke kan finde hexa-cd38 på CT. Men på EUs liste (link)
	23/3 17:35 af Plimsoller	(link)
	23/3 17:35 af Plimsoller	Glofitamab.
	23/3 17:27 af Helge Larsen/PI-redaktør	Jeps Bulder.
	23/3 17:27 af E L	Dara up to 14% of the frontline patients, last time we heard i think was 12%?
	23/3 17:26 af Solsen	Masser af potentiale i de stoffer vi kender.
	23/3 17:26 af Bulder	I morgen kommer der SH-tal. Holder du udkig Helge? Gerne for januar også.
	23/3 17:26 af Solsen	CD37 glæder jeg mig også til...
	23/3 17:24 af Helge Larsen/PI-redaktør	Tak GB og tusinde tak til alle for de skarpe spørgsmål. Desværre var der ikke plads til dem alle indenfor tidsrammen.
	23/3 17:23 af E L	I don't understand why he didn't give us the Dara price hike; he did so the last 2 times? Maybe there was no hike... Has anyone seen it anywhere else?
	23/3 17:20 af E L	so I guess we learned there is a maximum to the time JNJ can think about HexaBody-CD38 , which is they 'can in theory wait for the clinical data from two clinical studies'
	23/3 17:19 af GeorgeBest	Tak til Helge for at arrangere denne unike mulighed for interaction med JvdW :-)
	23/3 17:19 af E L	and then hope the dose they end up with is small enough to put it through in SC
	23/3 17:18 af E L	IV offcourse for now
	23/3 17:17 af Solsen	Hvad mon CT siger
	23/3 17:17 af Solsen	Jeg tvivler stærkt på at HALO skal involveres i hexacd38
	23/3 17:17 af Mcjean	Yep det eneste tidspunkt han havde sin "det kører bare" hat på:-)
	23/3 17:16 af peter12	Ja og han lyder optimistisk ;-)
	23/3 17:03 af Solsen	Hexa38 lyder super interessant på Q&A
	23/3 16:38 af svak	tak - exitnu
	23/3 16:36 af exitnu	Her: (link)
	23/3 16:33 af svak	Hvor følger vi o&a - der er ikke noget under fanen?
	23/3 16:15 af Solsen	NBI nede med 2,5% og Genmab kun 1% ... positivt ;-)

	23/3 16:14 af Solsen	SLE er en oplagt indikation for dara, som man ikke forstår hvorfor JNJ ikke har angrebet.
	23/3 16:08 af Helge Larsen/PI-redaktør	Q&A starter kl. 15,30. :-)
	23/3 16:07 af E L	we had a few articles indicating Dara would work here and in september an article where this Berlin hospital announced they would start a trial
	23/3 16:04 af E L	New smal trial - An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematosus (DARALUP) (link)
	23/3 15:35 af Bulder	Det kan være. Jeg ved ikke specifikt om glofi.
	23/3 15:34 af GeorgeBest	14:13 @Bulder: men referencen til subcu kan jo være relateret til Mosunetuzumab, hvor vi har vist siden sidste efterår at Roche vil udvikle en subcu version
	23/3 15:26 af troldmanden	two closely....
	23/3 15:26 af troldmanden	We always need human trials. But its to closly related molecules, so there is a lot that can be compared in preclinical models vs dara clinical data
	23/3 15:15 af E L	troldmanden are you essentially saying they can estimate toxicity already in those preclinical models? (i can understand efficacy, but thought you would need it in human to find out how toxic it is?)
	23/3 15:14 af Bulder	Men epco kan jo komme først som sc.
	23/3 15:13 af Bulder	Ja: Robust development programmes are ongoing for mosunetuzumab and glofitamab, investigating the treatments as monotherapies and in combination with other molecules, as well as more convenient forms of administration such as subcutaneous administration, with several phase III trials planned in the near future.(link)
	23/3 15:11 af GeorgeBest	Bulder: har vi set noget konkret på om Roche vil udvikle en subcu version for Glofitamab?
	23/3 15:09 af Bulder	For konkurrence vil der blive.
	23/3 15:08 af Bulder	Det er bl.a. Martin Hutchings begejstring for bispecifikke antistoffer, som gør at jeg tror på epco. Spørgsmålet er så, hvor stor en markedsandel epco vil kunne få.
	23/3 15:01 af Bulder	ienk1: Nej det er en ny (i øvrigt god baggrunds-)artikel, men vi havde forleden lidt debat om glofi vs epco pba en netop offentliggjort videnskabelig artikel, som også er nævnt i indledningen til dit link.
	23/3 14:55 af troldmanden	EL they should have a VERY god picture of that already when they compare thier preclinical PK models
	23/3 14:43 af ienk1	jeg ved ikke om den hr været vist før (link)
	23/3 14:32 af E L	Health Canada approves Kesimpta® (link)
	23/3 13:57 af E L	I doubt he'll be able to answer that, until they know what their optimal dose will be
	23/3 13:26 af troldmanden	Jeg har stillet spørgsmål til Jan ang Hexacd38 vs HALO. Så må vi se om Helge får plads til spørgsmålet :-)
	23/3 13:13 af Helge Larsen/PI-redaktør	Aktier/middag: Zealand og Norden tager teten i surt marked (link)
	23/3 12:48 af E L	neither do I. But I think we can rest assured that Genmab will do whatever they can to get this into SC themselves if possible lol
	23/3 12:47 af GeorgeBest	No
	23/3 12:45 af E L	and you are now assuming HexaCD38 will not need HALO, are you sure?
	23/3 12:45 af E L	I agree, just saying they may wait with deciding that. And the longer they wait, the more development costs for Genmab.
	23/3 12:43 af GeorgeBest	I understand the issue with hexacd38. But if it is significantly better than dara, they should follow that path. Just to fend off competition like Sarclisa, CAR-T and many other. Furthermore they would cut off HALO with a move to hexacd38...